IDEAYA Biosciences (IDYA) News Today $27.64 +0.44 (+1.62%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$28.04 +0.40 (+1.45%) As of 10/3/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IDYA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Upgraded by Wall Street ZenOctober 3 at 12:30 AM | marketbeat.comPlatinum Investment Management Ltd. Has $3.51 Million Stake in IDEAYA Biosciences, Inc. $IDYAOctober 2 at 6:35 AM | marketbeat.comIDEAYA Biosciences Earns Relative Strength Rating Upgrade; Hits Key BenchmarkSeptember 30, 2025 | msn.comVoya Investment Management LLC Has $377,000 Stock Position in IDEAYA Biosciences, Inc. $IDYASeptember 28, 2025 | marketbeat.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 26, 2025 | prnewswire.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 24, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Coverage Initiated by Analysts at GuggenheimSeptember 19, 2025 | marketbeat.comGuggenheim Initiates Coverage of IDEAYA Biosciences (IDYA) with Buy RecommendationSeptember 19, 2025 | msn.comRhumbline Advisers Boosts Stock Position in IDEAYA Biosciences, Inc. $IDYASeptember 18, 2025 | marketbeat.comIdeaya Biosciences initiated with a Buy at GuggenheimSeptember 17, 2025 | msn.comWoodline Partners LP Has $5.17 Million Position in IDEAYA Biosciences, Inc. $IDYASeptember 15, 2025 | marketbeat.comMizuho Boosts IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $44.00September 14, 2025 | marketbeat.comMizuho Securities Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)September 13, 2025 | theglobeandmail.comCould IDEAYA Biosciences' (IDYA) Expanding Pipeline Redefine Its Long-Term Value Proposition?September 13, 2025 | finance.yahoo.comLeerink Partnrs Has Negative Outlook of IDYA FY2026 EarningsSeptember 13, 2025 | marketbeat.comIdeaya Biosciences price target raised to $44 from $43 at MizuhoSeptember 12, 2025 | msn.comIDEAYA Biosciences (NASDAQ:IDYA) Trading 5.6% Higher Following Analyst UpgradeSeptember 11, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $38.00 at Royal Bank Of CanadaSeptember 11, 2025 | marketbeat.comStephens Reaffirms Overweight Rating for IDEAYA Biosciences (NASDAQ:IDYA)September 11, 2025 | marketbeat.comIDEAYA Biosciences' (IDYA) "Overweight" Rating Reiterated at Cantor FitzgeraldSeptember 11, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 6.4% - What's Next?September 10, 2025 | marketbeat.comCitizens JMP Initiates IDEAYA Biosciences (IDYA) With a Buy RatingSeptember 10, 2025 | insidermonkey.comBarclays Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)September 10, 2025 | theglobeandmail.comCitizens JMP Initiates IDEAYA Biosciences (IDYA) With a Buy RatingSeptember 10, 2025 | msn.comIDEAYA Biosciences Gets Relative Strength Rating UpgradeSeptember 9, 2025 | msn.comIdeaya Biosciences price target raised to $38 from $36 at RBC CapitalSeptember 9, 2025 | msn.comIDEAYA Biosciences: Positive Darovasertib Data In Neo-Adjuvant Melanoma Sets Next CatalystSeptember 9, 2025 | seekingalpha.comTrexquant Investment LP Lowers Stock Position in IDEAYA Biosciences, Inc. $IDYASeptember 9, 2025 | marketbeat.com11,908 Shares in IDEAYA Biosciences, Inc. $IDYA Purchased by American Century Companies Inc.September 9, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (IDYA) 10-Year Anniversary R&D Day (Transcript)September 8, 2025 | seekingalpha.comIDEAYA Biosciences, Inc. (IDYA) Special Call - SlideshowSeptember 8, 2025 | seekingalpha.comIDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial CancerSeptember 8, 2025 | prnewswire.comIDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal MelanomaSeptember 8, 2025 | prnewswire.comIDEAYA Biosciences, Inc. $IDYA Shares Sold by Adage Capital Partners GP L.L.C.September 8, 2025 | marketbeat.com190,421 Shares in IDEAYA Biosciences, Inc. $IDYA Acquired by Cubist Systematic Strategies LLCSeptember 8, 2025 | marketbeat.comIDEAYA Biosciences (IDYA) Has a New Rating from BarclaysSeptember 8, 2025 | theglobeandmail.comIDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung CancerSeptember 7, 2025 | prnewswire.comBarclays Upgrades IDEAYA Biosciences (NASDAQ:IDYA) to Strong-BuySeptember 7, 2025 | marketbeat.comIDEAYA Biosciences, Inc. $IDYA Shares Sold by Northern Trust CorpSeptember 7, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Coverage Initiated by Analysts at Citizens JmpSeptember 6, 2025 | marketbeat.comWedbush Increases Earnings Estimates for IDEAYA BiosciencesSeptember 6, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Trading Up 5.1% on Analyst UpgradeSeptember 5, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysSeptember 5, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Takes Position in IDEAYA Biosciences, Inc. $IDYASeptember 5, 2025 | marketbeat.comJMP Securities Initiates Coverage of IDEAYA Biosciences (IDYA) with Market Outperform RecommendationSeptember 5, 2025 | msn.comIDEAYA Biosciences (IDYA) Gets a Buy from Mizuho SecuritiesSeptember 5, 2025 | theglobeandmail.comIdeaya Biosciences enrolls first patient in IDE397 trialSeptember 4, 2025 | msn.comBarclays Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight RecommendationSeptember 4, 2025 | msn.comIDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up - Should You Buy?September 4, 2025 | marketbeat.comRedmile Group LLC Reduces Position in IDEAYA Biosciences, Inc. $IDYASeptember 4, 2025 | marketbeat.com Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDYA Media Mentions By Week IDYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IDYA News Sentiment▼1.020.54▲Average Medical News Sentiment IDYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IDYA Articles This Week▼47▲IDYA Articles Average Week Get the Latest News and Ratings for IDYA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for IDEAYA Biosciences and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Verona Pharma PLC American Depositary Share News Revolution Medicines News Grifols News Rhythm Pharmaceuticals News Avidity Biosciences News Abivax News Legend Biotech News Cytokinetics News Nuvalent News Axsome Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IDYA) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IDYA Stock Alerts